Antibody-drug conjugates are revolutionizing the cancer treatment landscape.
We have been working with Bioconjugates since 2006, with a focus on manufacturing antibody-drug conjugates (ADC) to treat cancer.
Today we manufacture the majority of commercial ADC's, producing more than 300 cGMP batches a year.
Learn more about how our unique setup simplifies the supply chain, accelerates timelines, and reduces costs: [ Ссылка ]
